Hepatic hemangioma: proportion and predictor of surgical treatment with emphasis on its growth rate.
Arteriovenous malformation
Hemangioma
Liver
Surgery
Journal
The Korean journal of internal medicine
ISSN: 2005-6648
Titre abrégé: Korean J Intern Med
Pays: Korea (South)
ID NLM: 8712418
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
06
02
2023
accepted:
09
06
2023
medline:
10
11
2023
pubmed:
9
11
2023
entrez:
8
11
2023
Statut:
ppublish
Résumé
There are limited studies on the management of hepatic hemangiomas (HHs). We investigated the proportion and predictors of surgical resection and analyzed HH growth rates in addition to associated factors. A retrospective case-control study of patients treated in 2 centers was conducted. Thirty-six patients who underwent surgical resection were assigned to the case group. Patients who did not undergo surgical treatment were randomly sigselected at a 1:10 ratio and assigned to the control group (n = 360). Baseline characteristics, clinical course and surgical outcomes were analyzed. The proportion of surgically treated HH patients was 0.3% (36 per 11,049). The longest diameter at diagnosis (mean ± standard deviation) was 7.7 ± 5.2 cm in the case group and 2.4 ± 1.8 cm in the control group (p < 0.001). In the multivariate analysis, the presence of more than 2 HHs (odds ratio [OR] 7.64, 95% confidence interval [CI] 1.40-41.72) and a growth rate of more than 4.8%/year (OR 30.73, 95% CI 4.86-194.51) were independently associated with surgical treatment. Symptom development during follow-up was related to HH size > 10 cm (OR 10.50, 95% CI 1.06-103.77, p = 0.04). The subgroup analysis showed substantial growth in 41.3% with an overall mean annual growth rate of 0.14 cm. Approximately one in 300 patients with an HH underwent surgical treatment. Multiple HHs and a growth rate of more than 4.8%/year were indications for surgical treatment. Nearly half of the HHs showed growing pattern in our study.
Sections du résumé
BACKGROUND/AIMS
There are limited studies on the management of hepatic hemangiomas (HHs). We investigated the proportion and predictors of surgical resection and analyzed HH growth rates in addition to associated factors.
METHODS
A retrospective case-control study of patients treated in 2 centers was conducted. Thirty-six patients who underwent surgical resection were assigned to the case group. Patients who did not undergo surgical treatment were randomly sigselected at a 1:10 ratio and assigned to the control group (n = 360). Baseline characteristics, clinical course and surgical outcomes were analyzed.
RESULTS
The proportion of surgically treated HH patients was 0.3% (36 per 11,049). The longest diameter at diagnosis (mean ± standard deviation) was 7.7 ± 5.2 cm in the case group and 2.4 ± 1.8 cm in the control group (p < 0.001). In the multivariate analysis, the presence of more than 2 HHs (odds ratio [OR] 7.64, 95% confidence interval [CI] 1.40-41.72) and a growth rate of more than 4.8%/year (OR 30.73, 95% CI 4.86-194.51) were independently associated with surgical treatment. Symptom development during follow-up was related to HH size > 10 cm (OR 10.50, 95% CI 1.06-103.77, p = 0.04). The subgroup analysis showed substantial growth in 41.3% with an overall mean annual growth rate of 0.14 cm.
CONCLUSION
Approximately one in 300 patients with an HH underwent surgical treatment. Multiple HHs and a growth rate of more than 4.8%/year were indications for surgical treatment. Nearly half of the HHs showed growing pattern in our study.
Identifiants
pubmed: 37939665
pii: kjim.2023.062
doi: 10.3904/kjim.2023.062
pmc: PMC10636540
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
818-830Références
JAMA Surg. 2014 Dec;149(12):1266-71
pubmed: 25321079
AJR Am J Roentgenol. 1997 Jul;169(1):137-40
pubmed: 9207513
Ann Transl Med. 2021 Jul;9(13):1067
pubmed: 34422979
Cardiovasc Intervent Radiol. 2021 Jan;44(1):80-91
pubmed: 32808203
HPB (Oxford). 2014 Oct;16(10):924-8
pubmed: 24946109
Sci Transl Med. 2016 Mar 30;8(332):332ra42
pubmed: 27030594
Hepatol Res. 2016 Jul;46(8):727-33
pubmed: 26492419
Liver Int. 2006 Apr;26(3):334-8
pubmed: 16584396
Am J Gastroenterol. 2014 Sep;109(9):1328-47; quiz 1348
pubmed: 25135008
AJR Am J Roentgenol. 1987 Nov;149(5):953-7
pubmed: 3314430
J Clin Gastroenterol. 2005 May-Jun;39(5):401-12
pubmed: 15815209
Am J Med Genet. 2002 Apr 1;108(4):257-64
pubmed: 11920828
Oncol Rep. 2001 Mar-Apr;8(2):411-4
pubmed: 11182065
Hepatogastroenterology. 2007 Mar;54(74):475-9
pubmed: 17523302
Gut. 1991 Jun;32(6):677-80
pubmed: 2060877
Int J Mol Sci. 2022 Feb 21;23(4):
pubmed: 35216474
Surgery. 2017 Jun;161(6):1514-1524
pubmed: 28126252
Am J Surg. 2004 Feb;187(2):181-91
pubmed: 14769302
Clin Mol Hepatol. 2018 Jun;24(2):163-168
pubmed: 28719965
J Clin Epidemiol. 1994 Sep;47(9):971-5
pubmed: 7730913
Nat Genet. 2009 Jan;41(1):118-24
pubmed: 19079259
Pediatr Dermatol. 2005 Sep-Oct;22(5):383-406
pubmed: 16190987
HGG Adv. 2021 Apr 8;2(2):
pubmed: 33912852
Surg Today. 2008;38(5):463-8
pubmed: 18560973
Radiology. 1994 Apr;191(1):111-3
pubmed: 8134554
J Hepatol. 2016 Aug;65(2):386-98
pubmed: 27085809
Gut. 2004 Sep;53(9):1352-5
pubmed: 15306599
J Exp Med. 2020 Jul 6;217(7):
pubmed: 32405640
J Clin Med. 2021 Sep 25;10(19):
pubmed: 34640399